Comparing EUS-guided and conventional therapy to prevent rebleeding in liver cancer patients
Official title: Secondary Prevention of Variceal Rebleeding by Endoscopic Ultrasound-guided Therapy Versus Conventional Endoscopic Therapy in Hepatocellular Carcinoma Patients: a Randomized Controlled Trial
Run by Chinese University of Hong Kong · NCT05629845 · Data updated 2026-11-12
This study is testing whether a new ultrasound-guided treatment can better prevent rebleeding in liver cancer patients compared to the usual treatment.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 84 (estimated) |
| Sponsor | Chinese University of Hong Kong Academic / other |
| Locations | 1 site (Shatin, New Territories) |
| Status | Recruiting |
| Started | November 22, 2022 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | March 19, 2026 |
| Trial ID | NCT05629845 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are HCC patients aged 18 or older who have recently experienced and successfully controlled variceal bleeding.
✕Probably not a fit
Patients who may not benefit from this study include those with non-variceal sources of gastrointestinal bleeding or severe comorbidities that contraindicate endoscopy.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to evaluate the effectiveness of endoscopic ultrasound (EUS)-guided therapy versus conventional endoscopic therapy in preventing variceal rebleeding in patients with hepatocellular carcinoma (HCC). It focuses on patients who have recently experienced variceal bleeding and have had their bleeding controlled through standard endoscopic methods. The study will compare the rates of rebleeding following these two therapeutic approaches, with a particular emphasis on the high-risk population of HCC patients. The methodology involves a multicenter approach to gather comprehensive data on patient outcomes.
Why it matters
Potential benefit: If successful, this study could significantly reduce the rates of rebleeding in HCC patients, improving their overall survival and quality of life.
How similar studies have gone: Previous studies have shown promising results with EUS-guided therapies in similar patient populations, indicating potential for success in this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Consecutive HCC patients age 18 or older with recent (within 4 weeks of the episode) EV or GV bleeding successfully controlled by conventional endoscopic therapies (VBL for EV or glue injection for GV) * Able to provide written informed consent to participate in the study and comply with the study procedures Exclusion Criteria: * Unable to provide written informed consent * Contraindications for endoscopy due to underlying comorbidities * HCC patients with non-variceal source of gastrointestinal bleeding * Refractory coagulopathy (INR\>1.5) or refractory thrombocytopenia (platelets \<50,000) despite blood product transfusion * Moribund patients from terminal illness
Where it's running
-
Prince of Wales Hospital, The Chinese University of Hong Kong
Shatin, New Territories, Hong Kong Recruiting
Study contacts
- Principal investigator: Raymond S Tang, MD — Chinese University of Hong Kong
- Study coordinator: Raymond S Tang, MD
- Email: raymondtang@cuhk.edu.hk
- Phone: (852) 26370428
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
InstaSure Non-Invasive Finger-Press Test for HCC
This study tests a non-invasive finger-skin test to help identify hepatocellular carcinoma in adults.
-
BGB-B2033 vs Sorafenib or Lenvatinib for advanced liver cancer
This study tests whether the investigational drug BGB-B2033 can help people with advanced hepatocellular carcinoma when given after prior PD-1/PD-L1 therapy, compared with the standard medicines sorafenib or lenvatinib.
-
Zinc add-on with targeted therapy plus immunotherapy for advanced liver cancer
This study tests whether adding daily zinc to standard targeted therapy and immunotherapy helps people with unresectable or advanced hepatocellular carcinoma.
-
68Ga-SorB PET/CT imaging for solid tumors
This study tests a new PET tracer called 68Ga-SorB to see if it can safely and accurately detect tumors in adults with melanoma, liver, lung, breast, pancreatic, ovarian cancer, or cholangiocarcinoma.
-
Hepatocellular Carcinoma Patient Registry (CHARM Hepatocellular Carcinoma MEA)
This observational study collects medical records of adults with hepatocellular carcinoma to understand how the disease presents and progresses across regions in the Middle East and North Africa.
-
GLP-1 RA plus standard treatment in first-line metastatic GI cancers
This early-phase trial tests whether adding a GLP-1 receptor agonist to standard first-line chemotherapy is safe and feasible for people with metastatic pancreatic, colorectal, or liver cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.